Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

World’s Largest Study on Sleep Apnea Suggests Apps Improve Patient Adherence


Sleep Apnea

This observational study followed patients using sleep apnea devices, which were remotely monitored by their physician, or by themselves.

Share this!

October 26, 2016 | by Sarah Hand, M.Sc.

According to the results of a 128,000-patient study conducted by ResMed, sleep apnea patients who use a self-management app in conjunction with positive airway pressure (PAP) are more likely to adhere to their therapy. ResMed is a global medical device company, focused on using cloud-based apps to help patients manage their chronic disease.

“This new study shows that online self-monitoring tools engage patients and significantly improve their compliance and adherence to treatment,” said ResMed Medical Director Dr. Adam Benjafield. “While our study focused on PAP users, we believe these results may be generalized more broadly in terms of the role online tools can have in improving medical treatment compliance overall.”

According to ResMed, poor patient adherence to treatment places an estimated $290 billion burden on the US healthcare system every year. Poor adherence increases the likelihood of disease progression, and these patients are more likely to be admitted to the hospital.

This observational study followed patients using sleep apnea devices, which were remotely monitored by their physician, or by themselves. ResMed’s myAir cognitive behavior-based app was used to monitor the patient’s adherence to the therapy.

Over 87 percent of PAP users were compliant when using myAir for self-monitoring, in conjunction with AirView for clinician remote monitoring. Patients who were only monitored using AirView showed 70 percent compliance to their therapy. Despite advances in continuous positive airway pressure (CPAP) therapy for sleep apnea patients, as few as 50 percent of people adhere to the therapy in the absence of digital monitoring.

“Half of all patients don't take their medications as prescribed, and we know that same statistic holds true for compliance with PAP therapy for sleep apnea,” said Benjafield. “The effects of poor treatment adherence are profound, not only for the number of people suffering due to poor medication adherence, but also in terms of emergency room visits, hospitalizations and their financial burden to the healthcare system.”

As a companion to AirView, myAir could help patients ensure they’re following the proper advice of their clinician on how to best manage their sleep apnea. ResMed will present further study data at this year’s American College of Chest Physicians (CHEST) annual meeting.

Keywords: Sleep Apnea, Patient Adherence, Medical Device


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.